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Summary
Purpose This phase 1 study examined safety, pharmacokinetics (PK), and efficacy of the poly(ADP-ribose) polymerase (PARP)
inhibitor ABT-767 in patients with advanced solid tumors and BRCA1/2 mutations or with high-grade serous ovarian, fallopian
tube, or primary peritoneal cancer. Methods Patients received ABT-767 monotherapy orally until disease progression or unac-
ceptable toxicity. Dose was escalated from 20mg once daily to 500 mg twice daily (BID). Dose-limiting toxicities, recommended
phase 2 dose (RP2D), food effect, objective response rate, and biomarkers predicting response were determined. ResultsNinety-
three patients were treated with ABT-767; 80 had a primary diagnosis of ovarian cancer. ABT-767 demonstrated dose-
proportional PK up to 500 mg BID and half-life of ~2 h. Food had no effect on ABT-767 bioavailability. Most common grade
3/4 treatment-related adverse events were nausea, fatigue, decreased appetite, and anemia. Anemia showed dose-dependent
increase. RP2D was 400 mg BID. Objective response rate by RECIST 1.1 was 21% (17/80) in all evaluable patients and 20%
(14/71) in evaluable patients with ovarian cancer. Response rate by RECIST 1.1 and/or CA-125 was 30% (24/80) in patients with
ovarian cancer. Mutations in BRCA1 or BRCA2, homologous recombination deficiency (HRD), and platinum sensitivity were
associated with tumor response. Median progression-free survival was longer for HRD positive (6.7 months) versus HRD
negative patients (1.8 months) with ovarian cancer. Conclusions ABT-767 had an acceptable safety profile up to the established
RP2D of 400 mg BID and dose-proportional PK. Patients with BRCA1 or BRCA2 mutation, HRD positivity, and platinum
sensitivity were more sensitive to ABT-767.
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Introduction
Poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 are nu-
clear enzymes that recognize DNA damage and facilitate DNA
repair [1, 2]. Malignancies with deficiencies in homologous
recombination, such as those with breast cancer gene (BRCA)
mutations, are more dependent on PARP for DNA repair than
normal cells and are therefore more sensitive to PARP inhibi-
tion [3]. Accordingly, monotherapy PARP inhibitors have
shown antitumor activity in BRCA mutated tumors [4–8].
In patients with breast cancer, mutations in the BRCA1/2
genes account for 5% of all breast cancers and 15–20% of all
hereditary breast cancers [9, 10]. BRCA1/2 mutations also
account for an increased risk of early-onset prostate cancer,
gastric and pancreatic cancer [11]. Approximately 20% of
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high-grade serous ovarian cancers (HGSOC) have a germline
or somatic BRCA1/2 mutation, and approximately 50% over-
all have a defect in homologous recombination [12]. The stan-
dard treatment for ovarian cancer is surgical debulking and
chemotherapy; however, many patients develop resistance to
platinum-based chemotherapy after the first or subsequent
treatment cycles [13].
ABT-767 is a potent, oral, competitive inhibitor of PARP-1
(Ki = 0.47 nM) and PARP-2 (Ki = 0.85 nM). This compound
has shown single-agent anti-tumor activity in patients with
HGSOC and BRCA-mutated solid tumors [14]. Here, we eval-
uated the safety/tolerability, pharmacokinetics (PK), food ef-
fect, and efficacy of ABT-767 in patients with advanced solid
tumors with BRCA1/2 mutations, and in patients with
HGSOC, fallopian tube, or primary peritoneal cancer.
Materials and methods
Patients
Patients were screened at three sites in the Netherlands.
Eligible patients were 18 years or older with histologically
or cytologically confirmed malignancy that was metastatic
or unresectable, and for which standard curative measures
did not exist or were no longer effective. All patients had
either a documented deleterious BRCA1 or BRCA2 mutation
or high-grade serous ovarian, fallopian tube, or peritoneal
cancer, Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of 0 to 2, and adequate hematologic, renal and
hepatic function. In the Expanded Safety Cohort #1, all pa-
tients had a documented deleterious BRCA1/2 mutation, a
lesion accessible for biopsy, and measurable disease per
Response Evaluation Criteria in Solid Tumors (RECIST), ver-
sion 1.1. In the Expanded Safety Cohort #2, all patients had a
known positive or negative status for deleterious BRCA1/2
mutation. Patients in the Expanded Safety Cohort #2 with
ovarian cancer could have non-measurable disease in case of
an elevated serum cancer antigen-125 (CA-125) level by
Gynecologic Cancer Intergroup (GCIG) criteria.
Patients were not eligible if they received anti-cancer ther-
apy within 28 days or 5 half-lives (whichever was shorter) of
first dose of study drug, if they had central nervous system
metastases, unresolved clinically significant toxicities from
their prior anti-cancer therapy, clinically significant uncon-
trolled condition(s), or if they were pregnant or breastfeeding.
In the Expanded Safety Cohorts, patients were not eligible if
they had received a prior PARP inhibitor.
Study design and treatment
This was a phase 1, open-label, non-randomized, dose-
escalation study (NCT01339650) of ABT-767 to
determine the dose-limiting toxicities (DLTs), maximum
tolerated dose (MTD) and the recommended phase 2 dose
(RP2D). ABT-767 was administered orally to patients on
days 1–28 of 28-day cycles. Patients continued to receive
ABT-767 until they experienced progression per RECIST
1.1 or unacceptable toxicity. Intra-patient dose escalation
was allowed in patients who experienced clinical worsen-
ing or who had stable disease and who may benefit from
dose escalation in the opinion of the investigator.
Patient cohorts were administered ascending doses of
ABT-767. The initial dose was 20 mg once daily (QD).
Doses for subsequent cohorts were administered twice daily
(BID) and were doubled until a grade 2 toxicity occurred
during cycle 1; following a grade 2 toxicity, dose escalations
were restricted to between 25% and 75% of the previous dose.
The decision to escalate the dose was based on observed
DLTs, other adverse events, and PK data. A modified 3 + 3
design was used to determine MTD and RP2D. Each dose
level included at least 3 evaluable patients but could enroll
up to 9 patients. If one patient within any dose level experi-
enced a DLT, the cohort was expanded to at least 6 patients.
The dose could be escalated if >67% of patients in a cohort did
not experience a DLT in Cycle 1. MTD was defined as the
highest dose level at which less than 2 out of 6 patients or
<33% of patients experienced a DLT. The RP2D was defined
by observed DLTs and determination of MTD.
After determination of RP2D, additional patients were
enrolled to two Expanded Safety Cohorts to further eval-
uate the safety, tolerability, and PK of ABT-767 at the
RP2D. Food effect was assessed in the Expanded Safety
Cohort enrolling patients with BRCA1/2 germline muta-
tion and advanced solid tumors only.
Safety and tolerability
Safety was evaluated throughout the study through assess-
ment of treatment-emergent adverse events (TEAEs) and
laboratory tests. TEAEs were reported according to the
National Cancer Institute Common Terminology Criteria
for Adverse Events (CTCAE) version 4.03. Treatment-
related TEAEs were those considered possibly or proba-
bly related to ABT-767.
The following TEAEs were considered DLTs if occurring
during the first cycle of dosing and attributed to ABT-767:
grade 4 absolute neutrophil count (ANC), grade 3 ANC last-
ing more than 7 days, or ≥ grade 3 ANC with fever; ≥ grade 3
thrombocytopenia; ≥ grade 3 decreased hemoglobin; non- he-
matologic toxicities of CTCAE ≥ grade 3 that have increased
at least 2 grade levels from baseline (except nausea, vomiting,
diarrhea, and tumor pain that have not received optimal treat-
ment); creatinine increases to grade 3 that are not corrected to
grade 1 or baseline within 24 h by IV fluids; ≥ grade 3 meta-
bolic toxicities not corrected to ≤ grade 2 within 24 h or any
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symptomatic grade 4 metabolic toxicity; or grade 2 non-
hematologic toxicities representing ≥2 grade increase from
baseline requiring dose modification or delay of >1 week.
Pharmacokinetics
ABT-767 was administered as a single dose under fasting
conditions on day −4 (for patients being evaluated for food
effect) and as either QD or BID under non-fasting conditions
on study days 1 through 28. ABT-767 PK samples were col-
lected at 0, 0.5, 1, 1.5, 2, 4, 6, 8, 10 and 24 h post-dose on
Cycle 1 Days −4, 1, and 8. Urine sample collections started
immediately after the ABT-767 morning dose on Cycle 1 Day
7 and ended immediately prior to the morning dose on Cycle
1 Day 8. Maximum observed plasma concentration (Cmax),
the time to Cmax (peak time, Tmax), and the area under the
concentration curve (AUCt) were determined using non-
compartmental methods.
Exploratory efficacy
Objective response rate (ORR: confirmed complete re-
sponse [CR] plus partial response [PR]) was based on
RECIST version 1.1, and was evaluated in patients with
measurable disease at baseline. Tumor marker CA-125 re-
sponse was measured by GCIG criteria [15] in patients
with ovarian cancer, and was evaluated in patients with a
pre-treatment sample within 2 weeks of starting treatment
that was at least twice the upper limit of normal. Time of
progression-free survival was defined as the number of
days from first dose of study drug to disease progression
or death if disease progression was not reached. Six-month
progression-free survival (PFS) rate was calculated.
Biomarker analysis
BRCA status was collected at screening if known. A known
BRCA status was required for patients in the expansion co-
horts. Tumor BRCA1/2 mutation status and homologous re-
combination deficiency (HRD) score were analyzed using a
next generation sequencing assay (Myriad) in patients provid-
ing tissue samples in a central lab [16]. Tumors were consid-
ered HRD positive if they had an HRD score ≥ 42 and/or a
BRCA1/2 mutation, as previously described [17].
Statistical analysis
All patients who received at least one dose of ABT-767 were
included in the safety, PK, and efficacy analyses. For all sta-
tistical analyses, unless otherwise stated, statistical signifi-
cance was determined using a two-sided p value ≤0.05. The
Kaplan-Meier method was used to estimate PFS. Data were
analyzed both by specific ABT-767 dose cohort and in some
cases by pooling multiple cohorts.
Dose, BRCA mutation status, platinum sensitivity,
baseline CA-125 level (if relevant), and age were exam-
ined as potential predictive variables for efficacy (PFS
and best tumor response) and safety (anemia). A logistic
regression analysis was performed to characterize the
dose-response relationship between the ABT-767 dose
and best tumor response (CR or PR).
Results
Patient characteristics and treatment exposure
A total of 93 patients were enrolled and treated in the dose
escalation (n = 63) or expanded safety (n = 30) cohorts.
Patient demographics and baseline clinical characteristics are
summarized in Table 1. The majority of patients (86%) had a
primary diagnosis of ovarian cancer, and 45% (42/93 patients)
had known germline BRCA1/2 mutations.
The median duration of ABT-767 treatment among all 93
patients was 3.8 months (range 0.03–31.1) as of data cutoff on
March 29, 2016. The median duration for patients in the dose
escalation was 3.8 months (range 0.03–20.6), and the median
duration for patients in the expanded safety cohorts was
4.0 months (0.5–31.1).
Dose-limiting toxicities and recommended dose
DLTs occurred in three patients during the DLT evaluation
period; angina pectoris in one patient at 20 mg BID, and grade
3 anemia in two patients at 400 mg and 500 mg BID. The
RP2D was determined to be 400 mg BID. The 500 mg BID
dose was considered intolerable due to grade 3 anemia and
fatigue/general malaise.
Safety
Eighty-seven patients (93.5%) experienced at least one
treatment-related adverse event, and 40 patients (43%) expe-
rienced at least one grade 3 or 4 treatment-related TEAE.
Grade 3 or 4 treatment-related adverse events occurring in
more than one patient overall were anemia (31.2%), fatigue
(5.4%), decreased appetite (2.2%), neutropenia (2.2%), and
thrombocytopenia (2.2%) (Table 2). A dose-dependent in-
crease in all-grade anemia was observed with ABT-767 from
20 mg BID (16.7%) to 500 mg BID (66.7%). Mean hemoglo-
bin levels for all patients from screening visit to Cycle 3 Day 1
are shown in Supplemental Fig. 1.
Two patients had treatment-related TEAEs that led to discon-
tinuation (thrombocytopenia in one patient at 20 mg BID, and
decreased platelet count and anemia in one patient at 400 mg
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BID). Twenty-nine patients (31.2%) experienced at least one
TEAE that led to ABT-767 dose reduction; dose reduction
was due to anemia in 20 of these patients. Thirty-five patients
had a treatment-related TEAE that led to ABT-767 interruption.
Treatment-related TEAEs leading to dose reduction and inter-
ruption were generally more frequent with increasing dose.
Six patients (6.5%) experienced at least one treatment-related
serious TEAE (dizziness and angina pectoris in one patient;
decreased appetite, dehydration, and nausea in one patient; ab-
dominal pain, nausea, malaise, and vomiting in one patient; and
malaise, macular hole, and lung infection in one patient each).
Pharmacokinetics
ABT-767 exposure increased approximately dose-
proportionally from 20 mg to 500 mg (Fig. 1). The median
Table 1 Patient demographic and
baseline clinical characteristics Variable Dose escalation
(N = 63)
Expanded safety
(N = 30)
Total
(N = 93)
Sex, n (%)
Female 62 (98) 30 (100) 92 (99)
Age, years
Mean (SD) 57 (11) 59 (10) 58 (11)
Median (range) 57 (27–80) 60 (33–73) 58 (27–80)
Race, n (%)
White 63 (100) 28 (93) 91 (98)
Asian 0 2 (7) 2 (2)
Primary diagnosisa, n (%)
Ovarian, fallopian tube, or primary peritoneal 54 (86) 26 (87) 80 (86)
Fallopian tube, n 3 0 3
Primary peritoneal, n 2 1 3
Breast 7 (11) 3 (10) 10 (11)
Pancreatic 0 1 (3) 1 (1)
Prostate 1 (2) 0 1 (1)
Peritoneal mesothelioma 1 (2) 0 1 (1)
Prior therapies, n (%)
Number of prior therapies
1 9 (14) 4 (13) 13 (14)
2 17 (27) 11 (37) 28 (30)
3 11 (17) 5 (17) 16 (17)
4 15 (24) 8 (27) 23 (25)
≥ 5 11 (17) 2 (7) 13 (14)
≥ 1 PARP inhibitor-containing therapy 5 (8) 0 5 (5)
≥ 1 platinum-containing therapy 59 (94) 27 (90) 86 (93)
Platinum-free interval < 6 monthsb 32 (51) 10 (33) 42 (45)
Platinum-free interval 6–12 months 20 (32) 11 (37) 31 (33)
Platinum-free interval > 12 months 6 (10) 4 (13) 10 (11)
BRCA status, n (%)c
Germline BRCA1/BRCA2 mutation positive 26 (41) 16 (53) 42 (45)
Germline BRCA1/BRCA2 mutation negative 11 (18) 13 (43) 24 (26)
Germline BRCA1/BRCA2 mutation status unknown 26 (41) 1 (3) 27 (29
Abbreviations: PARP poly(ADP-ribose) polymerase; SD standard deviation
a 21 patients had a history of other malignancies including breast, colorectal, melanoma, renal, and basal or
squamous cell skin cancer
b Platinum-free interval was defined as the time in months between last dose of platinum-based therapy and start of
the next line of therapy. Platinum-free interval data are missing for 3 patients with prior platinum (1 in Dose
Escalation Cohort, and 2 in Expanded Safety Cohort). Patients with a platinum-free interval of <6, 6–12, and
>12 months were considered platinum resistant, partially platinum sensitive, and platinum sensitive, respectively
cBRCA1/2 mutation as reported by site at screening
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Tmax values ranged from 1.5 to 2.0 h under non-fasting con-
dition, and the harmonic mean half-life was approximately 2 h
across different cohorts (Supplemental Table 1). On average,
10% of ABT-767 dose was recovered as the parent drug in
urine, and renal clearance appeared to be independent of dose,
which suggests that renal clearance plays an important role in
ABT-767 elimination. The effect of food on the oral bioavail-
ability of ABT-767 was evaluated up to 400 mg ABT-767
dose, and no significant food effect was seen on Cmax or
AUC of ABT-767.
Efficacy
Among all patients, the objective response rate (CR + PR) by
RECIST 1.1 criteria was 21% ([17/80], 95% CI: 13–32%).
Among patients with ovarian cancer, the objective response
rate by RECIST 1.1 criteria was 20% ([14/71], 95% CI: 11–
31%), by GCIC (CA-125) criteria 35% ([23/35], 95% CI: 24–
48%), and by using RECIST 1.1 and/or CA-125 criteria 30%
([24/80], 95% CI: 20–41%). Duration of therapy and best
tumor response (RECIST 1.1) for individual patients are
shown in Fig. 2.
The best percentage change from baseline in tumor size by
ABT-767 dose is shown in Fig. 3. A ≥ 30% reduction from
baseline in tumor size was seen in 19 of 76 patients who had a
post-baseline measurement.
The 6-month PFS rate was 33% (95% CI: 23–42%) for all
patients, and 32% (95%CI: 22–42%) for patients with ovarian
cancer. The median PFS was 3.8 months (95% CI: 2.8–
5.2 months) for all patients, 3.7 months (95% CI: 2.7–
4.7 months) for patients with ovarian cancer, and 5.6 months
(95% CI: 1.8–7.7 months) for patients with other types of
primary cancer.
Biomarker analysis
Somatic BRCA mutation status and HRD status were deter-
mined for 60 patients with ovarian cancer for whom tissue was
submitted. Thirty-four patients had ovarian tumors that were
HRD positive; of these, 26 had deleterious BRCA mutations.
Of the 34 HRD positive patients, 16 (47%) were responders (7
PR, 9 CR) per RECIST 1.1 and/or CA-125 criteria; all 16
responders had prior platinum and 2 were platinum resistant.
Among the HRD positive patients who had a deleterious so-
matic BRCA mutation, 14/26 (54%) were responders (7 PR, 7
CR) per RECIST 1.1 and/or CA-125 criteria (Table 3).
Among the 8 patients who were HRD positive but had no
deleterious BRCA mutation, 2 were responders by RECIST
1.1 and/or CA-125 criteria. Both of these patients were par-
tially platinum sensitive, received ABT-767 at 400 mg BID
and had a CR. Among patients determined to be HRD nega-
tive, there were no responders per RECIST 1.1 or CA-125
criteria. Among HRD positive patients with ovarian cancer,
Fig. 1 Mean ± SD Cmax and
AUC10 after the morning dose of
ABT-767 on Day 1 of Cycle 1.
Abbreviations: Cmax maximum
observed plasma concentration;
AUC10 area under the plasma
concentration–time curve from
time 0 to 10 h
Table 2 Treatment-related
adverse events by frequency of
grade 3 or 4 events
Event, n (%) Dose Escalation (N = 63) Expanded Safety (N = 30) Total (N = 93)
All Grades Grade 3 or 4 All Grades Grade 3 or 4 All Grades Grade 3 or 4
Anemia 17 (27) 17 (27) 14 (47) 12 (40) 31 (33) 29 (31)
Fatigue 34 (54) 3 (5) 18 (60) 2 (7) 52 (56) 5 (5)
Decreased appetite 31 (49) 0 13 (43) 2 (7) 44 (47) 2 (2)
Neutropenia 1 (2) 1 (2) 2 (7) 1 (3) 3 (3) 2 (2)
Thrombocytopenia 2 (3) 2 (3) 0 0 2 (2) 2 (2)
Nausea 34 (54) 0 19 (63) 1 (3) 53 (57) 1 (1)
Leukopenia 0 0 2 (7) 1 (3) 2 (2) 1 (1)
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responses were generally more frequent in patients with fewer
prior therapies (Supplemental Table 2).
PFS was significantly longer in HRD positive patients with
ovarian cancer (median PFS 6.7 months; n = 34) compared
with HRD negative patients (median PFS 1.8 months; n =
26) (Log rank p < 0.0001) (Supplemental Fig. 2).
Predictors of response
In univariate analysis, platinum sensitivity (compared to plat-
inum resistant population) was a significant covariate
(p < 0.01) affecting best tumor response by RECIST, whereas
ABT-767 dose and BRCA mutational status (germline
compared to non-germline) showed a trend toward signifi-
cance (p < 0.1) (Supplemental Fig. 3). In multivariate analysis,
platinum sensitivity was a statistically significant covariate
affecting the best tumor response by RECIST (p < 0.01).
Both univariate and multivariate analyses revealed that PFS
is significantly affected by BRCA mutational status (germline
compared to non-germline; p < 0.05) and by platinum sensi-
tivity (platinum sensitive compared to platinum resistant pop-
ulation; p < 0.05) (Supplemental Fig. 3 B-C).
Discussion
This phase 1 study evaluated ABT-767 in patients with
ovarian cancer or BRCA mutations. ABT-767 had an ac-
ceptable safety profile up to the established RP2D of
400 mg BID. Anemia was the most common grade 3/4
Fig. 2 Efficacy data for
individual patients.
Abbreviations: BID twice daily;
MTD maximum tolerated dose;
QD once daily.
Germline BRCA status was
provided by the investigators.
Responses shown are best tumor
r e s p o n s e s ( REC I ST1 . 1 ) .
Arrowhead indicates patients still
on study. This plot does not
i n c l ude one pa t i e n t w i t h
peritoneal mesothelioma and no
BRCA1/2 mutation from the
50 mg BID cohort whose best
response was stable disease at
15 months
Fig. 3 Best percentage change
from baseline in tumor size by
ABT-767 dose in all patients.
Abbreviations: BID twice daily;
QD once daily.
Germline BRCA status was
provided by the investigators
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TEAE; onset of anemia was monitorable and was gener-
ally manageable with standard supportive care and dose
reduction. Anemia has been frequently reported with other
PARP inhibitors [4, 7, 8]. The half-life of ABT-767 was
approximately 2 h and renal clearance was a significant
pathway for ABT-767 elimination. The exposure to ABT-
767 increased approximately dose-proportionally from
20 mg to 500 mg. Food had no significant effect on
ABT-767 oral bioavailability up to 400 mg dose. The data
suggest that ABT-767 has single-agent activity in patients
with tumors with BRCA mutations or high-grade serous
ovarian cancer, with tumor responses of 21% (17/80 pa-
tients) in all patients per RECIST 1.1 criteria, and 30%
(24/80 patients) in patients with ovarian cancer per CA-
125 and/or RECIST 1.1 criteria.
Biomarker analyses indicate ABT-767 sensitivity among
HRD positive patients with ovarian cancer. PFS was signifi-
cantly prolonged in patients who were HRD positive, and ob-
served RECIST and/or CA-125 responses were generally re-
stricted to HRD positive patients. Responses were generally
more common among HRD positive patients who had a somat-
ic BRCA mutation compared to those who did not; however,
the sample size of HRD positive BRCAwild-type patients was
small at only 8 patients. Patient selection with a functional
HRD test [16] or RAD51 assay [18] may be useful for identi-
fying patients likely to respond. The biomarker analyses are
limited by the collection of tissue in a subset of patients, and
the inclusion of archived tissue that may have been from the
time of diagnosis in patients who received multiple prior lines
of therapy. It was observed that patients were generally less
likely to respond with increasing number of prior lines of ther-
apy.Mechanisms of resistance and possibleBRCA1/2 reversion
mutations were not evaluated in this study. Univariate and mul-
tivariate analyses showed that PFS is significantly affected by
BRCA mutation and platinum sensitivity, further delineating
patient populations that may benefit from therapy.
In this phase 1 study of ABT-767, responses were observed
in a refractory, heterogeneous patient population. Patients with
BRCA mutations, HRD positivity, and platinum sensitivity
were more sensitive to treatment, supporting that these popu-
lations are suitable candidates for PARP inhibitor therapy.
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